Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound Docetaxel in Pre-treated Pancreatic Cancer
NCT05616494Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of albumin-bound docetaxel in pancreatic cancer (PC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
albumin-bound docetaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05616494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05616494.